Cellular therapies carry immense promise to provide treatment for previously unmet disease areas, and hundreds of assets are currently in pre-clinical and clinical development. However, cell therapy companies today face numerous challenges at commercialization: high manufacturing costs, trouble sourcing key raw materials (e.g., viral vectors), long vein-to-vein turnaround times, lack of scalable manufacturing solutions, and limited market access. These challenges have prevented companies from meeting market demand, caused financial underperformance, and limited both patient drug access and clinical outcomes. Our discussion will explore possible solutions to the above issues and will address how companies can ensure long-term viability. Topics will include innovations in closed-system, “end-to-end” automated manufacturing technology and provider manufactured therapies, the effect of value-based performance reimbursement contracts, and the evolution and impact of allogeneic therapies.